Deal Theory: a Biopharma Deal Maker’s Approach to Maximizing Strategic Partnerships
Deal Theory In the summer of 2019, Locust Walk launched a blog post, Financing overhang or hangover: The impact on partnerships […]
Deal Theory In the summer of 2019, Locust Walk launched a blog post, Financing overhang or hangover: The impact on partnerships […]
Whitepaper Download: Inside Out Inside Out: Do Recent Acquisitions by “Big Pharma” Sound the Alarm for the Traditional R&D Model?
The impact on partnerships for public biotech companies CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends
The Asia Factor How Does a Smart Deal Maker “Play” this Region and Optimize the Capital Raising and Strategic Deal
Indication Selection for a Platform Company: The Faustian Dilemma CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market
Late-Stage Biopharma IPOs and the Commercialization Partnership – Predictor of Success? CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk
Key trends impacting Japan partnering CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends Multitrack Process Negotiation
Ask the Experts: The Importance of Including Subject Matter Experts in Deal Discussions CATEGORIES Asian Capabilities Capital Raising Commercial Assessment
The Best Buyers Are The Best Sellers CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends Multitrack
Maintaining Deal Momentum in the Summertime CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends Multitrack Process